Inpharma 1263 - 11 Nov 2000

■ The oncolytic virus agent CN-706* showsantitumour activity in prostate cancer, according to theresults of a study presented at the American Societyfor Therapeutic Radiology and Oncology, held recentlyin Boston, US. In this study, 20 men with prostatecancer which had not responded to radiotherapyreceived CN-706 at 1 of 5 doses. Of the 11 patientswho received 1 of the 2 highest doses, 9 hadreductions from baseline in prostate specific antigen(PSA) levels. A partial response occurred in 4 of thesepatients; the partial response was maintained for atleast 9 months in 3 patients.**

* Calydon; phase II** Partial response was defined as a reduction from baseline in PSAlevels of ≥ 50% for at least 4 weeks.

Calydon Inc. Experimental prostate cancer drug demonstrates antitumoractivity and acceptable safety profile. Media Release : [2 pages], 24 Oct 2000.Available from: URL: http://www.calydon.com 800839845

1

Inpharma 11 Nov 2000 No. 12631173-8324/10/1263-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved